Model and Relative Cost of Control Calculations A model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) to assess the relative costs of a single patient achieving each pre-specified single or composite endpoint in the three trials
Tirzepatide (Zepbound and Mounjaro): weekly vials you load into a syringe yourself or preloaded injection pens Semaglutide (Wegovy and Ozempic): weekly, preloaded injection pen in various doses Liraglutide (Saxenda and Victoza): daily injectable pens Other GLP-1s and weight-loss meds: Trulicity , a less common GLP-1 (dulaglutide), comes in the form of a pen for once-weekly injections Bydureon BCise (once-weekly preloaded injection) Rybelsus (oral method) Contrave and Xenical (weight-loss drugs that are not GLP-1s and typically come at a much cheaper price tag) Other medications: antibiotics, antidepressants, asthma medication, and much, much more Note: Ozempic, Mounjaro, Victoza, Trulicity, Bydureon, and Rybelsus are FDA approved for type 2 diabetes only and must be prescribed off-label for use as a weight-loss treatment
[21] Many of the claims in the MDL allege symptoms of gastroparesis, a condition in which the stomach muscles cannot operate properly to digest food
Therefore, it can be speculated that DPDPE or DPDPE-derivatives with higher potency may be more effective than current single-receptor agonists, like semaglutide
One particular success story is of a 38-year old mother who lost 20 pounds in her first 3 months of Wegovy after struggling with food cravings and emotional eating for years
